The World Health Summit brings together leading researchers, physicians, government officials and representatives from industry, non-governmental organizations (NGOs) and health care systems worldwide.
Speakers of the World Health Summit 2018 include (in alphabetical order):
Tedros Adhanom Ghebreyesus Tedros Adhanom Ghebreyesus, elected for a five-year term in May 2017, is the first WHO Director-General to have been elected from multiple candidates by the World Health Assembly, and is the first person from the WHO African Region to serve as WHO's chief technical and administrative officer. Prior to this election, he served as Ethiopia’s Minister of Foreign Affairs from 2012–2016. He served as Ethiopia’s Minister of Health from 2005–2012. In 2009, he was elected as Chair of the Global Fund to Fight AIDS, Tuberculosis, and Malaria Board.
Mazda Adli is a renowned expert for treatment of depression and stress-associated diseases. His focus lies on the topic “mental health for the urban population” and on the treatment and prevention of stress-associated mental diseases in our modern living environment. In 2009, he co-founded the World Health Summit with Detlev Ganten.
Dr Svetlana Akselrod from the Russian Federation has been appointed Assistant Director-General for Noncommunicable Diseases and Mental Health. She brings more than 15 years of experience in public health coordination and global health diplomacy. Prior to this role, Dr Akselrod was Coordinator at the WHO European Office for the Prevention and Control of Noncommunicable Diseases, where she oversaw WHO’s regional work to prevent and control noncommunicable diseases in eastern Europe and central Asian countries. In addition, she served as Deputy Director of the Department of International Cooperation and Public Affairs within the Ministry of Health of the Russian Federation between 2012 and 2016. In this capacity, she coordinated the government of the Russian Federation's global health engagement in key forums including the G8, G20 and BRICS summits, and the development of health programmes including those focused on noncommunicable in the Asia-Pacific Economic Cooperation (APEC) and Northern European countries. She has served on several global health committees and advisory groups both as a chair and member. In addition, she has represented the Government of the Russian Federation in the WHO Executive Board and for the World Health Assembly. She is trained as a paediatrician and holds a doctorate degree in public health as well as a diploma in international law
Klaus M. Beier is in charge of the undergraduate training of medical students in sexual medicine as well as postgraduate training for physicians and psychologists in this field. He is in charge of the outpatient clinic of the institute which offers assessment and treatment of the full range of sexual disorders and gender dysphorias. His current research focuses on the prevention of child sexual abuse.
Seth Berkley is Gavi’s CEO and d medical doctor specializing in infectious disease epidemiology. He founded the International AIDS Vaccine Initiative (IAVI) in 1996, where he served as President and CEO. Prior to that, he worked for the Health Sciences Division at The Rockefeller Foundation, held posts at the Center for Infectious Diseases, the US Centers for Disease Control; the Massachusetts Department of Public Health; and the Carter Center, where he was assigned as an epidemiologist to the Ministry of Health in Uganda.
Elizabeth Blackburn won the 2009 Nobel Prize in Physiology or Medicine for discovering the molecular nature of telomeres and the co-discovery of telomerase. Both telomeres and telomerase are thought to play central roles in aging and diseases such as cancer. She has shown an abiding commitment to public service in the scientific, academic and public policy arenas, and helped to guide public science policy.
An accomplished Corneal Surgeon and Ophthalmologist, Hélène Boisjoly is the first woman to hold the position of Dean of Faculty of Medicine at the University of Montreal and within the greater province of Quebec. She was the International President of the World Health Summit 2017.
Dr. Albert Bourla is the Chief Operating Officer (COO) of Pfizer, one of the world's premier innovative biopharmaceutical companies. As COO, Bourla oversees the company's commercial, strategy, manufacturing and global product development functions. He has almost 25 years of experience with Pfizer and has held a number of senior global positions across a range of markets and disciplines. Bourla is currently a board member of the Pfizer Foundation and the Biotechnology Innovation Organization (Bio), where he serves on the Executive Committee.
Prior to joining IFPMA, Thomas B. Cueni was Secretary General of Interpharma, the association of pharmaceutical research companies in Switzerland. For many years, he has been involved in the work of the European Federation of Pharmaceutical Industries and Associations, EFPIA, where he most recently served as Vice-Chair of the European Markets Committee and association representative on the Board. Prior to his appointment with Interpharma, he had a career as a journalist.
Working for the NCD Alliance since its founding in 2009, Katie Dain holds experience in organizational and strategic development, global advocacy and policy-making, program design as well as capacity-building in low- and middle-income countries. Before joining the NCD Alliance, she worked at the International Diabetes Federation in Brussels, leading their global advocacy program and establishing the first Women and Diabetes program.
Steve Davis, president and CEO of PATH, combines extensive experience as a technology business leader, global health advocate, and social innovator to accelerate great ideas and bring lifesaving solutions to scale. Over his career he has worked extensively on refugee programs and policies and Chinese politics and law. Davis is currently a lecturer on social innovation at the Stanford Graduate School of Business. He is also a member of the Council on Foreign Relations and sits on several advisory groups, including as a trustee of the World Economic Forum’s Global Health Challenge.
Professor Karl Max Einhäupl is a trained Neurologist. In 2004, he was awarded the German Federal Cross of Merit. From 1993-2008 Director of the Clinic for Neurology, Charité - Universitätsmedizin Berlin and from 2007 to 2008 Head of the Centre “CC15: Neurology, Neurosurgery and Psychiatry”. Since 2008, he is Chief Executive Officer of the Charité - Universitätsmedizin Berlin.
Before joining Wellcome in October 2013, Jeremy Farrar was Director of the Oxford University Clinical Research Unit in Vietnam for 18 years. His research interests were infectious diseases, tropical health and emerging infections. He has published over 500 peer-reviewed scientific papers and served as Chair on several advisory boards for governments and global organisations, including the World Health Organization. He is also a Fellow of both the Academy of Medical Sciences and the Royal Society.
Bill Gates is the principal founder of Microsoft and one of the richest and most influential people on Earth. Gates studied mathematics and computer science at Harvard in 1973 but dropped out to pursue his own coding. In 1976 Gates founded Microsoft, but it wasn’t until 1980 that the company got its big break when IBM approached them. In 1990 Microsoft released its first version of Windows and it soon became a best seller. Since 2008, Gates has focused his energy on working with his charitable foundation, “The Bill and Melinda Gates Foundation’ which he formed with his wife. His main areas of interest in philanthropy involve global issues ignored by the government. He is also interested in improving health and the environment.
Martin Hirsch holds his current position since November 2013. He used to be Head of the Emmaüs France, High Commissioner for Active Solidarity against Poverty, and the High Commissioner for Youth in the government of François Fillon. He holds a master's degree in Neurobiology and is an alumnus of the École Normale Supérieure and of the École Nationale d'Administration.
Adnan Hyder is Professor and Associate Chair in the Department of International Health. He is the Director of the Health Systems program, Director of the International Injury Research Unit, and Associate Director of Global Programs at the Johns Hopkins Berman Institute of Bioethics. He serves as Co-Director of the NIH-Fogarty International Research Ethics Training Program at the Bloomberg School of Public Health.
Ambassador Ischinger is Chairman of the Munich Security Conference (MSC) and Senior Professor for Security Policy and Diplomatic Practice at the Hertie School of Governance in Berlin. He has served as German Deputy Foreign Minister (State Secretary) and as Germany's Ambassador in Washington, D.C. and London. In 2015, he chaired an OSCE-mandated ‘Panel of Eminent Persons on European Security as a Common Project’. From 2008 to 2014, he was also Global Head of Government Relations at Allianz SE, Munich. He is a member of a number of non-profit and corporate boards.
As Executive Director, Dr Jayasree K. Iyer leads the strategic direction and stakeholder engagement of the Access to Medicine Foundation. She directs the research programmes for the Antimicrobial Resistance Benchmark, the Access to Medicine Index, the Access to Vaccines Index and specific studies into priority health topics, such as the recently-published ”Improving access to cancer care” report. To stimulate positive change within the pharmaceutical industry, Jayasree often speaks publicly on access-to-medicine matters on platforms hosted by international, governmental and non-governmental organizations, including the UN and WHO. In this capacity, she also engages with key pharmaceutical industry investors to support their engagement activities with pharma companies. She often refers to the Access to Medicine Index as a “book of solutions” for pharmaceutical companies working to improve their access footprints. Jayasree holds various postgraduate degrees (Masters and PhD) from Singapore and the John Hopkins School of Hygiene and Public Health. She has written many technical and research reports, book chapters and reviews, along with strategy papers for medicines for developing countries and solutions for neglected tropical diseases. Before joining the Foundation, Jayasree spent four years managing a portfolio of more than 25 public private partnerships between the Dutch government and the pharmaceutical industry, totalling a research budget of €150 million. These partnerships addressed cancer, immunology and neglected diseases. She has worked for various non-government organisations, academic institutions and was part of the founding team of a diagnostic service company in the US.
As a leading contributor to academic and political debates on governance for health at a national and global level, Ilona Kickbusch conducts global health diplomacy seminars in many regions and advises the World Health Organization (WHO). In Switzerland, she serves on the executive board of the Careum Foundation and as an advisor for Health 2020.
Frederik Kristensen, MD has been the Deputy CEO of CEPI since January 2017. Before joining CEPI he was a senior advisor on innovation at the World Health Organization in Geneva, in the Family, Women’s and Children’s Health Cluster. Dr. Kristensen is a healthcare executive with previous experience from the Norwegian Development Agency, hospital management and the pharmaceutical industry. He has started and run successful companies in the areas of health economics and decision support. At the start of his career he worked as a general practitioner in rural settings. He is an MD from the Universities of Oslo, Norway and Newcastle-upon-Tyne, UK, with a MPH/MBA degree from the University of California, Berkeley.
Susanna Krüger is CEO at Save the Children Germany e.V. since March 2016. Before she founded and led GoodRoots, an advisory firm working with social investors on their impact measurement and organizational change. Susanna's work experience includes over 16 years in development cooperation as well as humanitarian aid and its evaluation (Middle East, Asia and Africa), public administration reform, facilitation of organizational change in the non-profit sector, strategic philanthropy and impact investing efforts with large European foundations. Susanna holds master's degrees in history, philosophy and international law from the Free University in Berlin and in public administration from Harvard University.
In this role, he is responsible for defining Pfizer’s public policy positions and advancing government and public affairs strategies internationally. Prior to this role, McCarthy was the Chief Counsel for Pfizer’s Worldwide Research and Development division and responsible for Pfizer's global Intellectual Property activities. He serves on the Boards of the Business Council for International Understanding, the Global Intellectual Property Center (GIPC), and the United States Council for International Business.